OncoMatch/Clinical Trials/NCT04038619
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Is NCT04038619 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Loperamide for colitis.
Treatment: Loperamide — This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Ovarian Cancer
Endometrial Cancer
Breast Carcinoma
Cervical Cancer
Prior therapy
Must have received: checkpoint inhibitor
Treatment with any ICPI agent(s)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04038619 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received checkpoint inhibitor.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages